Takahashi I, Nakada H
Second Dept. of Medicine, Okayama University Medical School.
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1209-14.
Clinical effects of a low dose of behenoyl ara-C (LD-BHAC) and K-18, an IgG-melphalan conjugate, were studied in hypoplastic leukemia (HL). Among 8 cases of HL treated with LD-BHAC regimen, in which 50 mg BHAC was administered daily by one-hour drip infusion for 14 days, 4 achieved complete remission (CR) and 2, partial remission (PR). The response rate (CR + PR) was 75%. Hematological toxicities were observed in most of the cases. The peak level of serum ara-C concentration, 3.62-18.9 ng/ml (mean: 11.74 ng/ml), was observed at cessation of infusion, and an ara-C level of 2.75-48.9 ng/ml (mean: 3.45 ng/ml) was still present in the blood 6 hours after cessation of infusion. Six cases of HL were treated with K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. Two of 6 cases achieved CR with little hematological toxicities. LD-BHAC and K-18 can be expected in the treatment of hypoplastic leukemia and its related diseases such as hypoplastic preleukemia in the aged.
研究了低剂量山嵛酰阿糖胞苷（LD - BHAC）和IgG - 美法仑结合物K - 18对再生障碍性白血病（HL）的临床疗效。在接受LD - BHAC方案治疗的8例HL患者中，50 mg BHAC每日静脉滴注1小时，共14天，4例达到完全缓解（CR），2例达到部分缓解（PR）。缓解率（CR + PR）为75%。大多数病例观察到血液学毒性。静脉滴注结束时观察到血清阿糖胞苷浓度峰值为3.62 - 18.9 ng/ml（平均：11.74 ng/ml），静脉滴注结束6小时后血液中阿糖胞苷水平仍为2.75 - 48.9 ng/ml（平均：3.45 ng/ml）。6例HL患者接受K - 18治疗。每日给予8片K - 18，每片含30 mg。6例中有2例达到CR，血液学毒性轻微。LD - BHAC和K - 18有望用于治疗再生障碍性白血病及其相关疾病，如老年人的再生障碍性白血病前期。
